Skip to content
Screener

Castle Biosciences CSTL Business Segments — NET REVENUES

Similar metrics at other companies

Mediaco Holding Inc. logo
MDIAAudio — NET REVENUES
$9.76M-28.7%
Mediaco Holding Inc. logo
MDIAVideo — NET REVENUES
$21.62M+50.8%
Mediaco Holding Inc. logo
MDIABarter — NET REVENUES
$486K+10.7%
Mediaco Holding Inc. logo
MDIADigital — NET REVENUES
$15.54M+62.9%
Mediaco Holding Inc. logo
MDIAOther — NET REVENUES
$1.16M-25.2%
Mediaco Holding Inc. logo
MDIASyndication — NET REVENUES
$332K-50.3%

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$978.5M+76.1%
Enterprise value$951.46M+86.2%
P/S2.9×+1.3×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-031263
Line itemThree Months Ended March 31, 20262025
Net revenues from external customers(1)$83,679$87,988
Significant segment expenses:
Personnel costs58,36752,200
Organizational and marketing costs15,59414,229
Inventory usage6,4374,731
Clinical studies and publication costs2,5422,085
Professional services3,0073,576
Other segment items12,25437,015

Item 1. Financial Statements.

FAQ

What is Castle Biosciences's business segments — NET REVENUES?
Castle Biosciences (CSTL) reported business segments — NET REVENUES of $83.68M in Q1 2026.
How has Castle Biosciences's business segments — NET REVENUES changed year-over-year?
Castle Biosciences's business segments — NET REVENUES decreased by 4.9% year-over-year, from $87.99M to $83.68M.
What is the long-term trend for Castle Biosciences's business segments — NET REVENUES?
Over 3 years (2022 to 2025), Castle Biosciences's business segments — NET REVENUES has grown at a 35.9% compound annual growth rate (CAGR), from $137.04M to $344.23M.
What does business segments — NET REVENUES mean?
Represents the total gross revenue generated by the primary business segment after accounting for returns, allowances, and discounts. This metric serves as the top-line indicator of market demand and commercial success for the company's core product portfolio.

Ask your AI about Castle Biosciences's business segments — net revenues.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude